Fulcrum Therapeutics Announces Additional Series A Financing from GV
May 10, 2017
GV’s investment to drive continued momentum in the development of therapies for genetically defined diseases
Cambridge, Mass., May 10th, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of Fulcrum’s lead programs in Fragile X syndrome (FXS) and Facioscapulohumeral muscular dystrophy (FSHD).
“This financing is a testament to the great potential of our unique approach to treating serious diseases by modulating gene regulatory targets,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “We are thankful for the support of our investors as we continue to progress our lead programs in Fragile X and FSHD and work toward our goal of bringing a new generation of life-changing therapies to patients and families in need.”
Fulcrum was founded in July 2016 to discover and develop new medicines that restore health to patients and families by transforming gene regulation in disease. The company integrates recent advances in a range of biological disciplines to deliver on the promise of genomic medicine by creating innovative small molecule therapies that modulate the dynamic on and off switches that control gene regulation.
“Fulcrum approaches complex and untreated diseases through a novel lens, by developing therapeutics that attempt to target the gene regulation pathways rather than the genes themselves,” said Krishna Yeshwant, General Partner at GV. “Driven by the leadership of an accomplished CEO and academic researchers, we believe Fulcrum can alter the way we treat debilitating diseases that have profound effects on children and families.”
About Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.
Ten Bridge Communications